Good News | Hinova Pharmaceuticals' Deutenzalutamide Soft Capsules Included in the National Medical Insurance Drug Directory (2025)
On December 7, 2025, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Directory (2025)." Through national medical insurance negotiations, Hinova Pharmaceuticals' independently developed Deutenzalutamide Soft Capsules have been included in the National Medical Insurance Drug Directory for the first time. The directory will take effect on January 1, 2026.
First New Drug to Gain Medical Insurance Access
Deutenzalutamide Soft Capsules (formerly known as HC-1119 Soft Capsules) are a Class 1 new drug independently developed by the company for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a second-generation androgen receptor (AR) inhibitor and has received support from the National Major Science and Technology Project for New Drug Innovation.
The Phase 3 clinical data of Deutenzalutamide (HC-1119) conducted in China were selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023. The HC-1119-04 registration study of Deutenzalutamide was included in the 2023 CSCO Guidelines for the Diagnosis and Treatment of Prostate Cancer. The Phase 3 clinical study of Deutenzalutamide (HC-1119) in China met its primary endpoint. Data show that, compared with the control group, Deutenzalutamide significantly prolonged progression-free survival (PFS) and reduced the risk of disease progression or death by 42% (HR=0.58, 95% CI: 0.439–0.770; p=0.0001).
Deutenzalutamide Soft Capsules represent the first domestically developed innovative drug approved in China for the treatment of adult patients with mCRPC who have experienced disease progression after treatment with abiraterone acetate and chemotherapy and who have not previously received novel androgen receptor inhibitors. Compared with other novel endocrine therapies, Deutenzalutamide Soft Capsules demonstrate 内部技能lent safety profiles. It can significantly reduce the incidence of central nervous system adverse events (such as seizures and falls), has no rash-related adverse reactions, and reduces the risk of common complications in elderly patients. The 2025 CSCO Guidelines for the Diagnosis and Treatment of Prostate Cancer have included it as a recommended treatment option for mCRPC.
According to GLOBOCAN 2022 data, prostate cancer is a common malignant tumor of the urinary system, ranking second in incidence and fifth in mortality among cancers in men globally. In 2022, there were approximately 1.467 million new cases of prostate cancer worldwide. In recent years, the incidence of prostate cancer in China has shown an upward trend, with 134,000 new cases reported in 2022. With the accelerating aging of China's population, the number of prostate cancer patients continues to rise. According to Frost & Sullivan, the domestic prostate cancer market is expected to reach RMB 50 billion by 2030. According to incomplete statistics, the market size for second-generation anti-androgen drugs in China exceeded RMB 4 billion in 2024. For metastatic castration-resistant prostate cancer, endocrine therapy remains the recommended first-line treatment.
Risk Disclaimer
The inclusion of Deutenzalutamide Soft Capsules in the 2025 National Medical Insurance Drug Directory reflects the National Healthcare Security Administration's recognition of the drug's clinical value, patient benefits, and degree of innovation.
Following its inclusion in the medical insurance directory, the drug's market promotion will be facilitated, further reducing the medication burden on patients and improving drug accessibility. The National Medical Insurance Directory will officially take effect on January 1, 2026. The company will actively cooperate to promote the implementation of medical insurance policies, continue to advance hospital market access and core market coverage, and strive to meet patients' medication needs on a broader scale.
Specific information regarding medical insurance payment standards, reimbursement details, and other related matters shall be subject to the publicly disclosed information from the National Healthcare Security Administration and other relevant government departments.
Disclaimer:
1. Hinova Pharmaceuticals does not recommend the use of any unapproved drugs or for any unapproved indications.
2. The medical information contained in this press release is for informational and news reporting purposes only and is not intended for advertising purposes or as healthcare or diagnostic advice.
- Hinova's Clinical Trial Application for the Combination of HP501 Sustained-release Tablets and xanthine oxidase inhibitors in the Treatment of Hyperuricemia/Gout was Accepted by NMPA
- Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
- Hinova Announces Phase III Clinical Trial of Deutenzalutamide (HC-1119) in Chinese Patients with castration-resistant prostate cancer (mCRPC) Met Primary Endpoint
- Hinova Today Listed on the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock Exchange (SSE) in China, Relying on PROTAC and Deuterium Technology to Develop Innovative D


